5 assets in SAMD9L-Related Spectrum And Myeloid Neoplasm Risk

Therapeutic assets addressing SAMD9L-Related Spectrum And Myeloid Neoplasm Risk, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine SAMD9L-Related Spectrum And Myeloid Neoplasm Risk	Fred Hutchinson Cancer Center	P2	B (57)
Tacrolimus SAMD9L-Related Spectrum And Myeloid Neoplasm Risk	Fred Hutchinson Cancer Center	P2	B (57)
Treosulfan SAMD9L-Related Spectrum And Myeloid Neoplasm Risk	Fred Hutchinson Cancer Center	P2	B (57)
Methotrexate SAMD9L-Related Spectrum And Myeloid Neoplasm Risk	Fred Hutchinson Cancer Center	P2	CCC (55)
Lapine T-Lymphocyte Immune Globulin SAMD9L-Related Spectrum And Myeloid Neoplasm Risk	Fred Hutchinson Cancer Center	P2	CCC (48)